Neurizon Therapeutics (ASX:NUZ) agreed to redeem 1 million convertible notes held by Obsidian for a total consideration of about $1.2 million, with Obsidian agreeing not to sell Neurizon shares for two months following completion, according to a Thursday Australian bourse filing.
Upon completion, Obsidian will hold 750,000 convertible notes, the filing added.
Neurizon added that it remains fully funded through to the topline readout of the HEALEY ALS Platform Trial and completion of the study.
The company's shares fell past 8% in recent Thursday trade.